- Home
- GSIW vs SNOA Comparison
GSIW vs SNOA Comparison
Compare GSIW & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- SNOA
- Stock Information
- Founded
- GSIW 2016
- SNOA 1999
- Country
- GSIW Hong Kong
- SNOA United States
- Employees
- GSIW N/A
- SNOA N/A
- Industry
- GSIW
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- SNOA Health Care
- Exchange
- GSIW Nasdaq
- SNOA Nasdaq
- Market Cap
- GSIW 8.1M
- SNOA 7.5M
- IPO Year
- GSIW 2023
- SNOA 2007
- Fundamental
- Price
- GSIW $0.18
- SNOA $4.22
- Analyst Decision
- GSIW
- SNOA
- Analyst Count
- GSIW 0
- SNOA 0
- Target Price
- GSIW N/A
- SNOA N/A
- AVG Volume (30 Days)
- GSIW 13.8M
- SNOA 45.9K
- Earning Date
- GSIW 01-01-0001
- SNOA 11-06-2025
- Dividend Yield
- GSIW N/A
- SNOA N/A
- EPS Growth
- GSIW N/A
- SNOA N/A
- EPS
- GSIW N/A
- SNOA N/A
- Revenue
- GSIW $5,368,221.00
- SNOA $14,912,000.00
- Revenue This Year
- GSIW N/A
- SNOA $23.00
- Revenue Next Year
- GSIW N/A
- SNOA $24.59
- P/E Ratio
- GSIW N/A
- SNOA N/A
- Revenue Growth
- GSIW 283.23
- SNOA 17.43
- 52 Week Low
- GSIW $0.09
- SNOA $1.75
- 52 Week High
- GSIW $2.59
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- GSIW 54.81
- SNOA 50.01
- Support Level
- GSIW $0.14
- SNOA $3.72
- Resistance Level
- GSIW $0.16
- SNOA $4.60
- Average True Range (ATR)
- GSIW 0.02
- SNOA 0.21
- MACD
- GSIW 0.01
- SNOA 0.00
- Stochastic Oscillator
- GSIW 91.84
- SNOA 50.00
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.